NBTX (NBTX) Stock Price & Analysis
NBTX (NBTX) fell 3.89% to USD 34.34 as of June 10, 2026 at 07:55 UTC, according to Nexqual real-time market data.
NBTX last closed at USD 35.73; the session ranged USD 31.68–36.15 on volume of 109,532 shares. Market capitalization is $1.74B, with a 52-week range of USD 4.18–57.14 (NMS). Source: Nexqual, June 10, 2026 at 07:55 UTC.
Key Statistics (as of June 10, 2026 at 07:55 UTC)
| Price | USD 34.34 |
|---|---|
| Change | ▼ 3.89% (down) |
| Previous Close | USD 35.73 |
| Open | USD 35.47 |
| Day Range | USD 31.68 – 36.15 |
| 52-Week Range | USD 4.18 – 57.14 |
| Volume | 109,532 shares |
| Market Cap | $1.74B |
| Exchange | NMS |
Technical Analysis (NBTX)
Nexqual's technical model rates NBTX "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:55 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.43 (neutral) |
| vs SMA50 | Below (USD 37.24) |
| MACD | -0.85 (negative) |
Analyst Ratings (NBTX)
Wall Street analysts rate NBTX "Buy" based on 6 analysts, with a mean price target of USD 42.69 (range USD 29.56–69.82), per Nexqual as of June 10, 2026 at 07:55 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 42.69 |
| High Target | USD 69.82 |
| Low Target | USD 29.56 |
| Buy / Hold / Sell | 5 / 2 / 0 |
Earnings (NBTX)
| Next Earnings Date | 2026-03-31 |
|---|
Source: Nexqual, June 10, 2026 at 07:55 UTC.
Financials & Fundamentals (NBTX)
| Total Revenue | $32.59M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -196.42% |
| Profit Margin | -73.52% |
| Current Ratio | 1.09 |
| Total Cash | $52.75M |
| Total Debt | $95.32M |
| Free Cash Flow | $-7.89M |
Source: Nexqual, June 10, 2026 at 07:55 UTC.
Financial Health Score (NBTX)
Nexqual rates NBTX's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:55 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $53M cash vs $95M debt |
| Cash Flow | Weak — FCF negative: -$8M, burning cash |
| Efficiency | Mixed — No data |
Ownership (NBTX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +11.76% |
| Shares Outstanding | 50.79M |
| Float | 31.82M |
| Short % of Float | +0.09% |
Source: Nexqual, June 10, 2026 at 07:55 UTC.
Leadership (NBTX)
NBTX is led by Laurent Levy (age 52), Co-Founder, President of the Executive Board & CEO, per Nexqual as of June 10, 2026 at 07:55 UTC.
| Co-Founder, President of the Executive Board & CEO | Laurent Levy (age 52) |
|---|---|
| Chief Financial & Business Officer and Member of Executive Board | Bart Van Rhijn (age 51) |
| Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board | Leonard A. Farber |
| Chief Product Innovation & Delivery Officer | Anne-Sophie Lariviere |
Major Backers & Investors (NBTX)
Notable institutional backers of NBTX include Johnson & Johnson, according to Nexqual as of June 10, 2026 at 07:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Johnson & Johnson | 11.59% |
Source: Nexqual, June 10, 2026 at 07:55 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHVS | Pharvaris N.V. | USD 31.6 | ▲ 1.64% |
| IVA | Inventiva S.A. - American Depos | USD 3.97 | ▼ 1.49% |
| INBX | Inhibrx Biosciences, Inc. | USD 89.1 | ▲ 2.4% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 9.23 | ▲ 6.83% |
| OLMA | Olema Pharmaceuticals, Inc. | USD 10.45 | ▲ 1.36% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:55 UTC. This page is informational and not investment advice.